Tacalcitol is one of the analogues of vitamin D₃ used to treat plaque psoriasis. Its chemical structure is as follows:

with the chemical name: (1S, 3R, 5Z, 7E, 24R) – 9,10 – secocholesta – 5,7,10 – triene – 1,3,24 – triol. The clinical efficacy of the keratolytic product is difficult to assess taking into account the influence of others ingredients. The comparative studies of in vitro release testing and skin permeation provide a lot of details in the whole development of the manufacturing process.

The objective of this study was to compare the permeation of tacalcitol through human breast skin in the brand product versus a generic cutaneous lotion manufactured by Pharmaceutical Institute. Ex vivo permeation was investigated using a Franz diffusion cell. The method of the extraction was developed and the recovery was examined in the range from 5 ng to 50 ng of the active substance. The skin extracts were analysed using the HPLC method with normal phase at the flow rate 0.6 mL/min. and a UV detector. The concentration of tacalcitol was analysed in the stratum corneum and in both layers- epidermis/dermis. It was observed that the permeation of tacalcitol from both formulations tested was comparable.

• Legal notice:
  

  Copyright (c) Pielaszek Research, all rights reserved.
  The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
  In every case, proper references including Author(s) name(s) and URL of this webpage: https://science24.com/paper/28087 must be provided.

1. The comparison of the stability indicating  two HPLC methods and their application for the determination of bosentan in coated tablets 
2. Elaboration of travoprost eye drops formulation.
3. Determination of organic volatile impurities in Nepafenac by GC method
4. What modern crystallography can add to pharmaceutical research?
5. Antiproliferative and cytotoxic effect of vitamin D₃ and its derivatives on the selected cells with a higher proliferative potential
6. Application of the new data processing method for photodiode array detector in the analysis of drug substances
7. Validation of HPLC methods for analyzing the chemical purity of cilostazol
8. Identification of degradation products of cilostazol drug substance
9. The dissolution model and comparison of the analytical methods used for the assay of sunitinib malate released from capsules
10. Pharmaceutical  technologies  – why do they have to be innovative
11. Manufacturing of modified release tablets
12. A novel convergent synthesis of the prostaglandin F_2α analogues
13. An application of accelerator mass spectrometry (AMS) in pediatric clinical studies. Paracetamol, midazolam and spironolactone radiosynthesis and certification.
14. Application of HPLC for studying purity, content and release profile of temozolomide capsules
15. Development and validation of the HPLC-UV method for impurities determination in duloxetine hydrochloride
16. HPLC methods for in–process control and chemical purity determination of olopatadine
17. Development and validation of HPLC method. Review of selected cases.
18. HPLC method for determination of the enantiomeric purity of a new ω chain aldehyde synthon used in the synthesis of travoprost
19. Vitamin D analogs enhance the activity of imatinib mesylate in human non-small cell lung cancer model
20. Colon cancer treatment with the use of vitamin D analogs and irinotecan 
21. Synthesis and biological evaluation of new amino acid and dipeptide derivatives of neocryptolepine as anticancer agents. 
22. Experimental and theoretical charge density studies on a model analogue of vitamin D
23. Synthetic Technologies of Pharmaceutical Substances
24. Stability study of the coated tablets containing clopidogrel bisulfate as the active substance
25. Development of RP HPLC method for the analysis of calcipotriol in cream and ointment
26. Analytical control of synthesis and determination of BR-S by HPLC
27. HPLC method as an analitycal control of synthesis and determination of TZ-S
28. The synthesis of ezetimibe with high stereochemical purity
29. The influence of (24R)-1,24- dihydroxyvitamin D₃ on the anticancer activity of 5-fluorouracil in human colon cancer model
30. The use of the hyphenated LC-MS/MS technique for the characterisation of impurity profile of Quetiapine during drug development
31. A novel synthesis of 19-nor analogs of vitamin D
32. The influence of novel analogs of vitamin D₃ on the antiproliferative activity of cisplatin or doxorubicin on human promyelocytic leukaemia cell line HL-60 
33. Zolmitriptan synthesis and in-process control by HPLC methods
34. Isolation, structural elucidation and characterization of impurities in latanoprost
35. HPLC as a method for analytical control of synthesis and determination of tolterodine (TD-S)
36. New rosiglitazone salts
37. New calcipotriol analogs, their toxicity and antitumor activity in vivo in comparison to the affinity with VDR and DBP
38. High-yielded method of synthesis of voriconazole.
39. Development of HPLC and GC methods for analysis of Zolmitriptan of pharmaceutical purity
40. Polimorphism of Active Pharmaceutical Ingredients
41. HPLC AS A METHOD FOR ANALYTICAL CONTROL OF SYNTHESIS AND DETERMINATION OF PRAMIPEXOLE
42. ANTITUMOR EFFECT OF CISPLATIN OR FLUOROURACIL IN COMBINED TREATMENT WITH (24R)-1,24-DIHYDROXYVITA- MIN D₃
43. COMBINATION OF: IMATINIB, PRI-2191 AND CYTOSTATICS - THE ANTIPROLIFERATIVE EFFECTS ON HL-60 LEUKEMIA CELL LINE
44. ANTIPROLIFERATIVE ACTIVITY IN VITRO OF DIASTEREOMERIC ANALOGUES OF VITAMIN D3 AGAINST NORMAL AND CANCER CELL LINES